Tasigna News and Research

RSS
Cancer drug nilotinib found to be safe and well-tolerated in Alzheimer's disease clinical trial

Cancer drug nilotinib found to be safe and well-tolerated in Alzheimer's disease clinical trial

Cancer drug shows promise in battling Parkinson’s disease

Cancer drug shows promise in battling Parkinson’s disease

Study shows nilotinib drug is safe and well tolerated in patients with Parkinson's disease

Study shows nilotinib drug is safe and well tolerated in patients with Parkinson's disease

Study unravels how cancer medication works in brains of Parkinson's patients

Study unravels how cancer medication works in brains of Parkinson's patients

Novartis announces FDA approval of its first and only CML therapy with TFR data in product label

Novartis announces FDA approval of its first and only CML therapy with TFR data in product label

Inhibition of cell receptors clears toxic proteins, cuts inflammation and improves cognition in animal models

Inhibition of cell receptors clears toxic proteins, cuts inflammation and improves cognition in animal models

GUMC receives FDA clearance to begin clinical study of cancer drug in patients with Alzheimer's disease

GUMC receives FDA clearance to begin clinical study of cancer drug in patients with Alzheimer's disease

ADDF awards $2.1 million grant for clinical study of cancer drug in Alzheimer's patients

ADDF awards $2.1 million grant for clinical study of cancer drug in Alzheimer's patients

Novartis to highlight strength of its expanded oncology portfolio at ASCO 2015

Novartis to highlight strength of its expanded oncology portfolio at ASCO 2015

Novel targeted therapies and treatment combinations for leukemia

Novel targeted therapies and treatment combinations for leukemia

Novartis to highlight advances in blood, breast cancer research at ASH and SABCS 2014

Novartis to highlight advances in blood, breast cancer research at ASH and SABCS 2014

Preclinical data shows BGB324 as potential treatment option for Chronic Myeloid Leukemia

Preclinical data shows BGB324 as potential treatment option for Chronic Myeloid Leukemia

Studies confirm superiority of Tasigna to Glivec at achieving molecular response in Ph+ CML patients

Studies confirm superiority of Tasigna to Glivec at achieving molecular response in Ph+ CML patients

Novartis to present updates on broad cancer portfolio at ASH and SABCS symposiums

Novartis to present updates on broad cancer portfolio at ASH and SABCS symposiums

Experimental Therapeutics, Debiopharm join to develop oral small molecules targeting new class of epigenetic modulators

Experimental Therapeutics, Debiopharm join to develop oral small molecules targeting new class of epigenetic modulators

Finding solutions to protect U.S. troops against invisible killers

Finding solutions to protect U.S. troops against invisible killers

Novartis to highlight key data from extensive oncology portfolio at SABCS and ASH meeting

Novartis to highlight key data from extensive oncology portfolio at SABCS and ASH meeting

Ponatinib thwarts T315I gene mutation in chronic myeloid leukemia

Ponatinib thwarts T315I gene mutation in chronic myeloid leukemia

Ponatinib to earn gold-standard status for refractory chronic myeloid leukemia in 2015

Ponatinib to earn gold-standard status for refractory chronic myeloid leukemia in 2015

Researchers present results from 31 major studies of blood-related cancers at ASH 2011 meeting

Researchers present results from 31 major studies of blood-related cancers at ASH 2011 meeting